Exact Sciences stock holds above consensus target as valuation debate intensifies
Published on 08/19/2026 at 14:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exact Sciences (US30063P1057) stock is quoted at $104.91 as of August 19, 2026, leaving the shares above a widely followed consensus price target and underscoring a cautious view on valuation among analysts. Per an overview of the shares on a market-data portal dated August 19, 2026, the stock's current price compares with a consensus target of $98.21, implying 6.4% downside from this level and signaling that many observers see the shares as fully valued at today’s price. For investors, the gap between the live quote and the consensus target has become a central talking point around the diagnostics specialist.
Shares trade above consensus target
A detailed stock page for Exact Sciences updated on August 19, 2026 shows the shares at $104.91 with a stated consensus price target of $98.21, an explicit difference of $6.70 per share that translates to about 6.4% downside according to that same overview. The MarketBeat stock page for Exact Sciences indicates that the stock’s price is not only above the consensus target but also pressing toward the top of its documented 52-week range, which spans from $38.81 on the low end to $104.98 at the high end. That places the current $104.91 quote less than $0.10 below the 52-week high of $104.98, framing the move in the context of a strong multi-month run.
The same stock-page snapshot reports a market capitalization of $20.03 billion for Exact Sciences as of August 19, 2026, at the $104.91 share price. Within that context, the consensus rating highlighted in the overview is described as Reduce, with an average rating score of 1.95 based on 19 hold recommendations and 1 sell recommendation and no strong buy or buy ratings. The MarketBeat consensus summary therefore suggests a broadly cautious stance in which most covering analysts are neutral and at least one carries an outright negative view, consistent with the notion that the shares have rallied faster than underlying estimates.
Analyst stance and valuation context
According to the same MarketBeat consensus data for Exact Sciences updated on August 19, 2026, the average price target of $98.21 sits below the live price of $104.91, signaling that many analysts expect the stock to trade lower over their typical 12-month horizon if their assumptions hold. The downside-risk section of the MarketBeat page explicitly characterizes this gap as about 6.4% downside from the current price, reinforcing the message that the share price has moved ahead of the target range. Because the consensus rating is Reduce rather than Buy, the implied narrative is that while Exact Sciences continues to be an important player in molecular diagnostics for cancer, the stock’s valuation on August 19, 2026 is demanding relative to prevailing analyst models.
From an investor perspective, the contrast between the strong price level and the cautious consensus stance highlights a key debate: the degree to which Exact Sciences can keep growing revenue and earnings fast enough to justify a market capitalization of $20.03 billion. Although detailed quarterly figures are not visible in the same snapshot, the company’s positioning in cancer screening and diagnostics suggests that growth expectations are tied to adoption of its flagship tests, expansion into new indications, and potential operating leverage as volumes scale. In that sense, the 6.4% downside embedded in the consensus target is not a verdict on the business model itself but on the pace of growth relative to the current valuation.
Cancer screening platform supports the story
Exact Sciences is widely recognized for its suite of molecular diagnostic products designed for early cancer detection, most prominently noninvasive stool-based colorectal cancer screening that allows patients to test at home under physician guidance. The company’s tests combine advanced laboratory analysis with clear reporting back to clinicians, and that combination of convenience and diagnostic insight has helped drive broad awareness of the brand among both healthcare providers and patients. As more health systems and payers integrate molecular screening tools into routine preventive care, the potential addressable market for Exact Sciences’ offerings can expand, providing a foundation for revenue growth that investors monitor closely.
Beyond colorectal cancer screening, Exact Sciences has invested in expanding its oncology portfolio into additional indications such as advanced genomic profiling for solid tumors and blood-based tests under development that aim to detect cancer via circulating biomarkers. These initiatives are part of a strategy to build a multi-modality diagnostics platform rather than rely on a single product line. For shareholders evaluating the stock on August 19, 2026 at $104.91, the breadth and depth of the pipeline can influence how they view the trade-off between a higher valuation and future growth potential, even as the consensus target of $98.21 and Reduce rating indicate that analysts as a group prefer a more conservative stance.
Shares sit near 52-week highs
The 52-week trading range shown on the MarketBeat stock page, from $38.81 to $104.98, anchors the current price of $104.91 within a year-long context. The documented 52-week range underscores how dramatically the shares have climbed within the last year, moving from the $30s up to the low $100s. The fact that the current quote is only $0.07 below the 52-week high signals that the market has been willing to pay progressively higher prices for Exact Sciences stock in recent months, even as the consensus target has not caught up to that level.
For investors who bought the stock closer to the 52-week low of $38.81, the move to $104.91 represents a substantial gain in capital terms. While the precise percentage increase is not specified on the same page, the absolute change in dollar price illustrates the magnitude of the rally. At the same time, the Reduce rating and 6.4% downside embedded in the consensus target invite careful consideration of risk management for new entrants at the current price, suggesting that some market participants may prefer to await fresh financial results or guidance updates before extrapolating the recent trend further.
Representative product in colorectal cancer screening
A representative product for Exact Sciences is its noninvasive colorectal cancer screening test, marketed as a physician-prescribed at-home stool test that analyzes DNA markers associated with cancer and precancerous lesions. This product has been widely adopted in the United States as an alternative to traditional colonoscopy for certain patient populations, providing a more convenient and less invasive option that can boost screening participation. The core value proposition lies in early detection: by identifying cancer or high-risk lesions before symptoms arise, the test can help clinicians intervene earlier, improving patient outcomes and reducing downstream treatment costs.
From a business standpoint, the colorectal cancer screening test generates recurring revenue because patients are typically recommended to repeat screening on a regular schedule. As coverage by major insurers and public health programs has expanded, the addressable market for this product has grown. The test also serves as a gateway for Exact Sciences to deepen relationships with healthcare providers and payers, potentially enabling cross-selling of additional diagnostics from its oncology portfolio. For investors, the performance of this flagship product remains central to their assessment of the company’s long-term growth trajectory and its ability to sustain a market capitalization of $20.03 billion at a share price of $104.91 on August 19, 2026.
Exact Sciences stock valuation snapshot
Exact Sciences is listed on Nasdaq under the ticker EXAS, and the stock quote of $104.91 as displayed on August 19, 2026 comes with a stated market capitalization of $20.03 billion. The MarketBeat valuation overview frames this capitalization level alongside the consensus price target of $98.21 and the Reduce rating anchored in 19 hold and 1 sell recommendations, highlighting a divergence between market pricing and analyst expectations. For shareholders, this snapshot suggests that the stock currently embeds optimistic assumptions about future growth and execution in cancer diagnostics, while professional estimates remain more guarded.
For US retail investors following Exact Sciences stock on August 19, 2026, the key numerical anchors are therefore the $104.91 share price, the $38.81 to $104.98 52-week range, the $20.03 billion market capitalization, and the $98.21 consensus price target with its related indication of 6.4% downside. These figures capture a company whose shares have rallied toward the top of their historical range yet face a conservative analyst view on forward returns, making subsequent earnings reports, product adoption data, and guidance revisions important catalysts for potential re-rating over time.
Read more
Further details on Exact Sciences, including broader financial metrics and company background, are available on its Nasdaq-linked stock profiles and investor information pages operated by independent financial portals.
Fact box
Company: Exact Sciences Corp.
ISIN: US30063P1057
Ticker: EXAS
Exchange: Nasdaq
Price (as of August 19, 2026): $104.91 USD
Market cap: $20.03 billion (as of August 19, 2026)
Sector / Industry: Healthcare / Biotechnology
Index membership: Nasdaq index family
